Clinical trial · Interventional
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
NCT00610714CI-TRIAL-00008692OVERT-1completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD0530 | Drug | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Active Comparator
- description
- carboplatin plus paclitaxel
- interventionNames
- Drug: Carboplatin
- Drug: Paclitaxel
- type
- EXPERIMENTAL
- label
- 2
- description
- AZD0530 in combination with carboplatin plus paclitaxel
- interventionNames
- Drug: AZD0530
- Drug: Carboplatin
- Drug: Paclitaxel
Primary outcomes (1)
- measure
- Objective Response Rate as Evaluated by Response Evaluation Criteria In Solid Tumors ( RECIST)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have a diagnosis of advanced ovarian cancer * Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy * Estimated life expectancy of more than 12 weeks Exclusion Criteria: * Central Nervous System (CNS) metastases * Received more than 2 prior chemotherapy regimens for ovarian cancer treatment * Inadequate bone marrow reserve * Inadequate liver function, renal function or low haemoglobin * Pregnant, breastfeeding or if of child-bearing status unwilling to use an acceptable method of contraception
References
Publications (1)
- DERIVEDYap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583. PMID 19238149